Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS

Ocrelizumab (Ocrevus; Genentech) appears to have a more favorable safety profile in patients with multiple sclerosis (MS) compared to rituximab (Rituxan; Genentech and Biogen), according to a new analysis based on real-world data.¹

The findings…